Navigation Links
Pharmaxis Appoints French Distributor for Aridol(TM)
Date:3/10/2009

SYDNEY, March 11 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; NASDAQ: PXSL) is pleased to announce that it has appointed Praxis Pharmaceutical France SARL as its French marketer and distributer for the asthma diagnostic tool, Aridol.

Praxis Pharmaceutical is a recently established company created to introduce a portfolio of respiratory specialist products into the French pharmaceutical market. Praxis will complete the reimbursement application for Aridol in France and thereafter market the product to hospital specialists.

Dr Alan Robertson, Pharmaxis CEO said "We are delighted to announce this agreement and are looking forward to working with Praxis on developing the French market for Aridol. Aridol is a precisely engineered test that we believe will be an improvement on current practice. Aridol improves the identification of bronchial hyperresponsiveness which is one of the hallmarks of asthma."

The total population affected by Asthma in France is approximately 3.1 million. The French bronchial challenge testing market is dominated by methacholine and more than 25,000 tests are conducted annually with little recent innovation in the field. Aridol's ability to detect airway hyperresponsiveness in poorly controlled asthmatics offers information to the respiratory physician that has previously not been available.

Aridol is approved for sale in most major European countries, Australia and Korea. Aridol has been included in the Global Initiative for Asthma guidelines, and in the U.S. Asthma Management Guidelines. It is one of the tests recommended by the World Anti-Doping Agency, and other sports governing bodies to ensure elite athletes who are asthmatic are properly diagnosed and treated.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson -- Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:
     Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: felicity.moffatt@pharmaxis.com.au

    United States:
     Brandon Lewis, Trout Group
     Tel:   +1-646-378-2915
     Email: blewis@troutgroup.com

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmaxis Builds Senior Management Team
2. Pharmaxis Investor Conference Call
3. Pharmaxis Aridol Approved for Sale in Switzerland
4. Pharmaxis Investor Conference Call
5. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
6. New Pharmaxis Board Appointment
7. Pharmaxis Aridol Authorised for Sale in Germany
8. Pharmaxis First Steps into China
9. Pharmaxis to Apply to Market Bronchitol in Australia
10. Pharmaxis Investor Conference Call
11. Pharmaxis Aridol Gains First Asian Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... -- According to a new market report published ... A Streptococcus (GAS) Nucleic Acid (NA) Test Products Market - ... - 2023 ", the Europe molecular ... test products market was valued at US$ 8.3 Mn in ... 11.6% from 2015 to 2023 to reach US$ 22.3 Mn ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... release, Clinical Studio Version 4.1, greatly improves performance of the platform. In particular, ... often generate tremendous volumes of data to be collected on a per patient ...
(Date:5/5/2016)... ... 2016 , ... Proove Biosciences, Inc. today announced ... diagnostics company. The Algynomics platform and its patient cohorts provide researchers ... chronic pain, which will allow targeted preventive efforts, enhance patient stratification in clinical ...
(Date:5/5/2016)...  Why are two uber-successful former agency presidents ... launching a new venture—yet going about things in a ... helping clients raise the value of their offerings in ... type of collaboration. The result is Elevate, ... medical device sectors. Elevate specializes in shaping and transforming ...
Breaking Biology Technology:
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
(Date:3/11/2016)... , March 11, 2016 http://www.apimages.com ) ... Cross reference: Picture is available at AP Images ( http://www.apimages.com ) ... DERMALOG will be used to produce the new refugee identity cards. ... biometric innovations, at CeBIT in Hanover next ... from DERMALOG will be used to produce the new refugee identity ...
Breaking Biology News(10 mins):